A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes

AIMS: To assess the safety and efficacy of omarigliptin in Japanese patients with type 2 diabetes (T2D). METHODS: In a 24‐week double‐blind trial, 414 patients with T2D were randomized to omarigliptin 25 mg once weekly, sitagliptin 50 mg once daily or placebo. The double‐blind period was followed by...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Diabetes Obes Metab
Hoofdauteurs: Gantz, Ira, Okamoto, Taro, Ito, Yuka, Okuyama, Kotoba, O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Blackwell Publishing Ltd 2017
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655696/
https://ncbi.nlm.nih.gov/pubmed/28449368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12988
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items